Exploratory, Phase II, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GLPG0974 in Subjects With Mild to Moderate Ulcerative Colitis.
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2014
At a glance
- Drugs GLPG 0974 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Proof of concept
- Sponsors Galapagos NV
- 31 Aug 2018 Biomarkers information updated
- 24 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Feb 2014 Planned End Date in the ClinicalTrials.gov record has been changed from 1 January 2014 to 1 May 2014.